TrialLancet (London, England)2021

Adavosertib plus gemcitabine for platinum-resistant or platinum-refractory recurrent ovarian cancer: a double-blind, randomised, placebo-controlled, phase 2 trial.

Stephanie Lheureux et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.